The new cells prevented the onset of diabetes in an animal model of the disease bringing personalized cell therapy for diabetes closer.
Scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF) have successfully converted human skin cells into fully-functional pancreatic cells. The new cells produced insulin in response to changes in glucose levels, and, when transplanted into mice, the cells protected the animals from developing diabetes in a mouse model of the disease.
The new study, published in Nature Communications, also presents significant advancements in cellular reprogramming technology, which will allow scientists to efficiently scale up pancreatic cell production and manufacture trillions of the target cells in a step-wise, controlled manner. This accomplishment opens the door for disease modeling and drug screening and brings personalized cell therapy a step closer for patients with diabetes.
“Our results demonstrate for the first time that human adult skin cells can be used to efficiently and rapidly generate functional pancreatic cells that behave similar to human beta cells,” says Matthias Hebrok, PhD, director of the Diabetes Center at UCSF and a co-senior author on the study. “This finding opens up the opportunity for the analysis of patient-specific pancreatic beta cell properties and the optimization of cell therapy approaches.”
In the study, the scientists first used pharmaceutical and genetic molecules to reprogram skin cells into endoderm progenitor cells—early developmental cells that have already been designated to mature into one of a number of different types of organs. With this method, the cells don’t have to be taken all the way back to a pluripotent stem cell state, meaning the scientists can turn them into pancreatic cells faster. The researchers have used a similar procedure previously to create heart, brain, and liver cells.
After another four molecules were added, the endoderm cells divided rapidly, allowing more than a trillion-fold expansion. Critically, the cells did not display any evidence of tumor formation, and they maintained their identity as early organ-specific cells.
The scientists then progressed these endoderm cells two more steps, first into pancreatic precursor cells, and then into fully-functional pancreatic beta cells. Most importantly, these cells protected mice from developing diabetes in a model of disease, having the critical ability to produce insulin in response to changes in glucose levels.
“This study represents the first successful creation of human insulin-producing pancreatic beta cells using a direct cellular reprogramming method,” says first author Saiyong Zhu, PhD, a postdoctoral researcher at the Gladstone Institute of Cardiovascular Disease. “The final step was the most unique—and the most difficult—as molecules had not previously been identified that could take reprogrammed cells the final step to functional pancreatic cells in a dish.”
Sheng Ding, PhD, a senior investigator in the Roddenberry Stem Cell Center at Gladstone and co-senior author on the study, adds, “This new cellular reprogramming and expansion paradigm is more sustainable and scalable than previous methods. Using this approach, cell production can be massively increased while maintaining quality control at multiple steps. This development ensures much greater regulation in the manufacturing process of new cells. Now we can generate virtually unlimited numbers of patient-matched insulin-producing pancreatic cells.”
The Latest on: Personalized cell therapy
via Google News
The Latest on: Personalized cell therapy
- A Perfect Match: Molecular Tests Developed at MSK Guide Personalized Treatment for Lung Canceron November 25, 2020 at 1:23 pm
For personalized treatment to work, it’s important to analyze each person’s tumor for genetic mutations and find the best drugs to target those mutations.
- TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Marketon November 24, 2020 at 6:19 am
Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic ...
- Persephone Biosciences Initiates the ARGONAUT Study of Gut Microbiome-Linked Immune Modulation in Cancer Treatment Responseon November 23, 2020 at 6:33 am
Persephone Biosciences Inc., a biotechnology company that leverages real world data and artificial intelligence to design microbiome therapeutics and diagnostics to promote normal immune function and ...
- Researchers tackle sickle cell disease with CRISPR-based gene editingon November 23, 2020 at 5:23 am
Scientists at ChristianaCare's Gene Editing Institute have received a $1 million grant from the Lisa Dean Moseley Foundation to develop a novel gene therapy for inherited blood disorders including ...
- Cell Expansion Market Worth $30.1 billion by 2025 | Key Players are Thermo Fisher Scientific (US), Danaher (US), Becton, Dickinson and Company (US)on November 20, 2020 at 7:56 pm
The global cell expansion market is dominated by a few globally established players such as Thermo Fisher Scientific (US), Danaher (US), Becton, Dickinson and Company ...
- New findings speed progress towards affordable gene therapyon November 20, 2020 at 9:41 am
In a promising advance for affordable, personalized medicine, researchers have used metal-organic frameworks to successfully deliver the genetic snipping tool CRISPR/Cas9 into human cancer cells.
- SMART researchers develop gelatin microcarrier for cell productionon November 17, 2020 at 11:40 am
MIT Alliance for Research and Technology (SMART) developed a novel microcarrier for large-scale cell production and expansion that offers higher yield and cost-effectiveness.
- Anti-aging therapy useful against metastases, leading towards personalized therapy of patientson November 13, 2020 at 6:01 am
Andrea Alimonti, provides important information for personalized therapy of patients. Following specific therapies, aging tumor cells stop proliferating. This cell aging process is called senescence.
- Single cancer cell samples may boost custom treatmenton November 9, 2020 at 11:40 am
A 3D cell culture permits the formation of tumors ... address an individual patient’s cancer is the Holy Grail of personalized therapy, and now we’re one step closer,” Savran says.
- Biobanks Are Becoming Data Banks in the Era of Personalized Medicineon November 3, 2020 at 4:00 am
To support the development of personalized therapies, biobanks are meeting the data processing demands that arise when more samples—and more types of samples—are kept in circulation As we ...
via Bing News